Molecular Profiles Expands Capsule Capability

Molecular Profiles has expanded its capsule filling capability following significant investment into new equipment at its clinical manufacturing site in the United Kingdom.

Molecular Profiles, a subsidiary of Columbia Laboratories, announced that it has expanded its capsule filling capability following significant investment into new equipment at its clinical manufacturing site in the United Kingdom.

The CDMO has purchased a capsule bander, and can now offer liquid filling into capsules to complement its existing powder and semi-solid capsule filling capability.

Molecular Profiles has also added a second capsule filling machine that provides increased capacity, greater capsule fill weight range, and improved fill weight accuracy, with up to four-times the output of an existing machine.

“The investment in capsule banding is a natural extension to our oral dosage form manufacturing capabilities and will allow us to produce liquid-in-capsule formulations, which can be particularly beneficial for poorly soluble and potent compounds,” Rob Harris, chief technical officer at Molecular Profiles, commented in a press statement. “Given that many early phase trials tend to involve capsules, our new filling machine gives us much greater dosage flexibility. We can manufacture for relatively small-scale early-stage trials and also now have the enhanced capacity that allows us to scale up to Phase III.”

This additional capability marks the latest major investment at Molecular Profiles after the company recently created a new enabling technologies team and invested in GMP hot melt extrusion (HME) technology to further enhance its expertise in the processing of poorly soluble molecules. 

“We are often involved in the pre-formulation and formulation development of liquid-based dosage forms particularly when it involves overcoming solubility issues,” Harris added. “At this very early stage, our enabling technology platform facilitates our technical team in terms of screening compounds and selecting the most efficient development pathway for clients based on a foundation of science.” According to Harris, the new equipment provides the company with the full tool kit for manufacturing the full range of oral dosage forms.

Molecular Profiles works with pharma and biotech drug development organizations worldwide. The company specializes in advanced characterization, product development, clinical trials manufacturing, and analytical support. It manufacturers a range of dosage forms, including potent compounds and controlled drugs, spanning solids, liquids, and semi-solids such as capsules, tablets, and inhaled products.

Source: Molecular Profiles